# Domain QA: Strategy-Space Diagnostics Slice

## Status

Pass.

## Reviewed Inputs

- User-approved preferred-workflow plan
- `_workspace/00_input/request-summary.md`
- `README.md`
- `SPEC.md`
- `CHANGELOG.md`
- `docs/agent-playtest-protocol.md`
- `docs/mcp-playtesting-guide.md`
- `docs/playtest-findings-v0.1.51.md`
- `docs/playtest-findings-v0.1.52.md`
- `docs/playtest-findings-v0.1.54.md`
- `docs/playtest-findings-v0.1.55.md`
- `docs/playtest-findings-v0.1.56.md`
- `docs/harness/health-policy-strategy-game/team-spec.md`

## Findings

- Scope stays within the Phase 7 validation track: lightweight diagnostics over
  existing simulated-agent MCP evidence.
- The v0.1.56 artifact summarizes strategy clusters, outcome ranges, action
  frequency signals, evidence limits, and follow-up routing without changing
  mechanics, actors, scenario tooling, MCP contracts, or diagnostics tooling.
- Evidence limits are labeled clearly and do not claim human learning,
  empirical calibration, policy forecasting, equilibrium analysis, or balance
  validity.
- Competitive final metrics are read from published end-session debrief
  evidence and are not exposed during active play.
- No transition formulas, stochastic input resolution, rulesets, scenario files,
  campaign length, MCP DTO shapes, replay formats, or golden hashes changed.

## Required Fixes

None identified in the domain review.

## Residual Risks

- The diagnostic artifact is still based on small scripted and free-form
  simulated-agent samples.
- Market share appears only in v0.1.55 free-form competitive evidence.
- Any response to passive or low-benefit competitive choices should begin with
  player-facing guidance or debrief review, not formula tuning.

## Verification Evidence

- `python3 scripts/run_automated_playtests.py` completed 24 scripted sessions
  without validation failures.
- `cargo fmt --check` passed.
- `cargo test` passed: 222 unit tests, 8 integration tests, 0 doc tests.
- `git diff --check` passed.
